Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

ArborGen faces faster route to commercialisation in US

ArborGen faces faster route to commercialisation in streamlined US approval process

By Paul McBeth

March 16 (BusinessDesk) – Forestry biotech company ArborGen, which counts NZX-listed Rubicon as a major shareholder, may be on a quicker route to taking one of its products to market after US officials trimmed the timeline in the approval process of biotechnology products.

The US Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS) has outlined new processes to determine whether biotech products should be approved for commercial use, cutting the time to 13 to 16 months from an average three years per petition previously.

That means ArborGen could get its cold-tolerant eucalyptus product to market sooner than previously expected, provided it secures all the appropriate approvals.

“These process improvements announced by APHIS represent a significant improvement to the regulatory approval process previously in place, and these changes will be welcomed by the wider biotechnology community,” chief executive Andrew Baum, who was only appointed to lead the company this week, said in a statement. “The new process should achieve faster petition determinations without foregoing any of the rigour of APHIS’s environment assessment process.”

ArborGen wants to bring genetically-modified eucalyptus trees to market to enable production of the hardwood for pulp and biofuel in managed plantations in the south-eastern United States. The company has been selling varietal pine seedlings since 2006.

An early approval would be a fillip to the forestry biotech company, which was forced to shelve plans for an initial public offering last year as US financial markets struggled to revive in the wake of the global financial crisis, several years ago.

ArborGen’s shareholders Rubicon, International Paper and MeadWestvaco will have to source new funding to pursue a float, and may need to stump up more cash, tap private capital or seek new bank finance.

Shares in Rubicon climbed 5.4 percent to 39 cents in trading today.

(BusinessDesk)

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Super Fund/Canada Bid v NZTA: Tow Preferred Bidders For Auckland Light Rail

The two preferred delivery partners for Auckland light rail have been chosen and a final decision on who will build this transformational infrastructure will be made early next year, Minister of Transport Phil Twyford announced. More>>

ALSO:

9.3 Percent: Gender Pay Gap Unchanged Since 2017

“While it has remained flat since 2017, the gender pay gap has been trending down since the series began in 1998, when it was 16.2 percent,” labour market statistics manager Scott Ussher said. More>>

ALSO:

Ex-KPEX: Stuff Pulls Pin On Media Companies' Joint Ad-Buying Business

A four-way automated advertising collaboration between the country's largest media companies is being wound up after one of the four - Australian-owned Stuff - pulled the pin on its involvement as part of a strategic review of its operations ... More>>

Bus-iness: Transdev To Acquire More Auckland And Wellington Operations

Transdev Australasia today announced that it has agreed terms to acquire two bus operations in Auckland and Wellington, reaching agreement with Souter Investments to purchase Howick and Eastern Buses and Mana Coach Services. More>>

ALSO: